Rapid Micro Biosystems Exceeds Raised Guidance with Record Q4 and Full-Year 2025 Revenue Growth
RPID has more than doubled off its 52-week low of $1.021 on elevated volume (7.1× avg).
Summary
Rapid Micro Biosystems announced preliminary Q4 and full-year 2025 revenue that exceeded its raised guidance, driven by strong growth and record system placements.
Key Events · Earnings and Guidance · RPID
-
Record Q4 Revenue
Preliminary unaudited fourth quarter 2025 total revenue is expected to be approximately $11.3 million, representing a significant 37% growth compared to the prior-year period.
-
Exceeded Raised Guidance
The company's Q4 results surpassed its own raised guidance issued in November, indicating stronger-than-expected performance.
-
Strong Full-Year Performance
Full-year 2025 total revenue is expected to be approximately $33.6 million, achieving a 20% growth compared to the prior year.
-
Record System Orders and Placements
Rapid Micro Biosystems received a record multi-system order from an existing Top 20 global biopharma customer and placed 16 new Growth Direct systems in Q4 2025.
Analysis · RPID · Industrial Applications And Services
Rapid Micro Biosystems' preliminary Q4 and full-year 2025 revenue significantly exceeded its previously raised guidance, signaling strong operational execution and demand for its Growth Direct systems. The substantial year-over-year revenue growth, particularly the 37% increase in Q4, coupled with a record multi-system order from a major biopharma customer, indicates robust business momentum. This positive performance, especially in recurring revenue, suggests a healthy underlying business and could lead to increased investor confidence as the company enters 2026. The upcoming presentation at the J.P. Morgan Healthcare Conference provides an opportunity for management to elaborate on these results and future outlook.
At the time of this filing, RPID was trading at $3.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $134.7M. The 52-week trading range was $1.02 to $4.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.